Targeted Biomimetic Stem Cell Membrane–Exosome Composite Delivery System for the Treatment of Bone Defects

exerts its therapeutic effects by activating the TGF-β signaling pathway. These findings highlight an integration strategy for exosome-based therapy and offer a promising approach to overcoming current limitations in bone defect treatment, with substantial potential for clinical translation.